{"organizations": [], "uuid": "3231c1bd5aeddced307552af3e621637b4aa0363", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/7", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/22/business-wire-marc-goodman-joins-leerink-partners-equity-research-team.html", "country": "US", "domain_rank": 767, "title": "Marc Goodman Joins Leerink Partners Equity Research Team", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-05-22T16:00:00.000+03:00", "replies_count": 0, "uuid": "3231c1bd5aeddced307552af3e621637b4aa0363"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/22/business-wire-marc-goodman-joins-leerink-partners-equity-research-team.html", "ord_in_thread": 0, "title": "Marc Goodman Joins Leerink Partners Equity Research Team", "locations": [], "entities": {"persons": [{"name": "marc goodman", "sentiment": "negative"}, {"name": "goodman", "sentiment": "none"}], "locations": [{"name": "boston", "sentiment": "none"}, {"name": "new york", "sentiment": "none"}], "organizations": [{"name": "leerink partners equity research team", "sentiment": "negative"}, {"name": "leerink partners", "sentiment": "negative"}, {"name": "specialty pharmaceuticals", "sentiment": "none"}, {"name": "us healthcare analyst", "sentiment": "none"}, {"name": "ohio state university", "sentiment": "none"}, {"name": "ubs", "sentiment": "none"}, {"name": "cns", "sentiment": "none"}, {"name": "ubs investment bank", "sentiment": "none"}, {"name": "tufts university", "sentiment": "none"}, {"name": "equity research", "sentiment": "none"}, {"name": "crédit suisse ag", "sentiment": "none"}, {"name": "morgan stanley", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BOSTON--(BUSINESS WIRE)-- Leerink Partners, a leading healthcare investment bank, announces the hiring of Marc Goodman to the firm’s Equity Research team. Mr. Goodman joined the firm today as a Managing Director and Senior Research Analyst within the Therapeutics team. In this role Mr. Goodman will be leading the firm’s CNS therapeutics research efforts and will be located in the firm’s New York office.\nMr. Goodman joins the firm from UBS Investment Bank where he was most recently a Managing Director and US Healthcare Analyst focused on Large-Cap and Specialty Pharmaceuticals sectors. Prior to UBS, Mr. Goodman covered Specialty Pharmaceuticals and Generics sectors for over 15 years as a Managing Director at Crédit Suisse AG and an Executive Director at Morgan Stanley. He has a BA degree in economics from Tufts University and an MBA from Ohio State University.\nMr. Goodman has been ranked by Institutional Investor as a top analyst in Specialty Pharmaceuticals for well over a decade and has also expanded his coverage and interests into global and emerging biopharmaceutical companies in recent years.\n“The addition of Marc, with his extensive knowledge and experience, strengthens Leerink’s already powerful research offering at a time when client demand for a profound and differentiated research product is intensifying,” stated Jeff Leerink, Chairman and CEO of Leerink Partners. “We are committed to building the best healthcare research team in the industry and providing the deepest and most comprehensive research available.”\n“I’m excited that Marc has committed to join Leerink Partners. His experience in understanding corporate management teams, corporate strategy and regulatory pathways is a valuable addition to our biotherapeutics research team,” stated John L. Sullivan, CFA, Senior Managing Director of Equity Research at Leerink Partners. “Marc’s deep and longstanding relationships with institutional investors will serve Leerink well.”\n“I look forward to joining, what I believe to be, the top healthcare focused research franchise on the street,” said Mr. Goodman. “Leerink Partners is a firm that has the right strategy and team to be successful in the fast-changing financial services sector.”\nAbout Leerink Partners\nLeerink Partners LLC is a leading investment bank, specializing in healthcare. Our knowledge, experience and focus enable us to help our clients define and achieve their strategic, capital markets and investment objectives. We partner with companies that develop and commercialize innovative products and services that are defining the future of healthcare. Leerink Partners LLC is a member of FINRA/SIPC. For more information, please visit: www.leerink.com .\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180522005215/en/\nLeerink Partners\nDiane Vieira, 617-918-4097\nor\nWeber Shandwick\n617-520-7088\nSource: Leerink Partners", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.leerink.com&esheet=51809818&newsitemid=20180522005215&lan=en-US&anchor=www.leerink.com&index=1&md5=34c3f971d9415b1ec5694073156f0cbb", "https://www.businesswire.com/news/home/20180522005215/en/"], "published": "2018-05-22T16:00:00.000+03:00", "crawled": "2018-05-22T18:05:12.037+03:00", "highlightTitle": ""}